REFERENCES
1. Antunes C, Aleem A, Curtis SA. Gastroesophageal Reflux Disease. [Updated 2022 May 4]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK441938/ [accessed 27 April 2025].
2. Eusebi LH, Ratnakumaran R, Yuan Y, Solaymani-Dodaran M, Bazzoli F, Ford AC. Global prevalence of, and risk factors for, gastro-oesophageal reflux symptoms: a meta-analysis. Gut. 2018;67:430-40.
4. Lee JS. The Role of Gastroesophageal reflux and microaspiration in idiopathic pulmonary fibrosis. Clin Pulm Med. 2014;21:81-5.
5. Ghisa M, Marinelli C, Savarino V, Savarino E. Idiopathic pulmonary fibrosis and GERD: links and risks. Ther Clin Risk Manag. 2019;15:1081-93.
6. Latorre-Rodríguez AR, Razia D, Omar A, Bremner RM, Mittal SK. Pulmonary and esophageal function in lung transplantation: Fundamental principles and clinical application. Transplant Rev (Orlando). 2024;38:100796.
7. Masuda T, Mittal SK, Kovács B, et al. Foregut function before and after lung transplant. J Thorac Cardiovasc Surg. 2019;158:619-29.
8. Gao F, Hobson AR, Shang ZM, et al. The prevalence of gastro-esophageal reflux disease and esophageal dysmotility in Chinese patients with idiopathic pulmonary fibrosis. BMC Gastroenterol. 2015;15:26.
9. Gaude GS. Pulmonary manifestations of gastroesophageal reflux disease. Ann Thorac Med. 2009;4:115-23.
10. Baqir M, Vasirreddy A, Vu AN, et al. Idiopathic pulmonary fibrosis and gastroesophageal reflux disease: a population-based, case-control study. Respir Med. 2021;178:106309.
11. Méthot D, Leblanc É, Lacasse Y. Meta-analysis of gastroesophageal reflux disease and idiopathic pulmonary fibrosis. Chest. 2019;155:33-43.
12. Raghu G, Freudenberger TD, Yang S, et al. High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J. 2006;27:136-42.
13. Johannson KA, Strâmbu I, Ravaglia C, et al; Erice ILD Working Group. Antacid therapy in idiopathic pulmonary fibrosis: more questions than answers?. Lancet Respir Med. 2017;5:591-8.
14. Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184:1390-4.
15. Irwin RS. Chronic cough due to gastroesophageal reflux disease: ACCP evidence-based clinical practice guidelines. Chest. 2006;129:80S-94S.
17. Bremner RM, Mittal SK. Esophageal symptoms and selection of diagnostic tests. In Yeo CJ, Editor. Shackelford’s Surgery of the Alimentary Tract, 2 Volume Set: Amsterdam: Elsevier; 2019. pp. 44-56.
18. Ciovica R, Gadenstätter M, Klingler A, Neumayer C, Schwab GP. Laparoscopic antireflux surgery provides excellent results and quality of life in gastroesophageal reflux disease patients with respiratory symptoms. J Gastrointest Surg. 2005;9:633-7.
19. Matyásová Z, Novotná B, Matulová M et al. The relation of GERD, bronchial asthma and the upper respiratory tract. Vnitr Lek. 2005;51(12):1341-1350.
20. Raghu G, Pellegrini CA, Yow E, et al. Laparoscopic anti-reflux surgery for the treatment of idiopathic pulmonary fibrosis (WRAP-IPF): a multicentre, randomised, controlled phase 2 trial. Lancet Respir Med. 2018;6:707-14.
21. D'Ovidio F, Singer LG, Hadjiliadis D, et al. Prevalence of gastroesophageal reflux in end-stage lung disease candidates for lung transplant. Ann Thorac Surg. 2005;80:1254-60.
22. Hathorn KE, Chan WW, Lo WK. Role of gastroesophageal reflux disease in lung transplantation. World J Transplant. 2017;7:103-16.
23. Lo WK, Burakoff R, Goldberg HJ, Feldman N, Chan WW. Pre-transplant impedance measures of reflux are associated with early allograft injury after lung transplantation. J Heart Lung Transplant. 2015;34:26-35.
24. Razia D, Mittal SK, Bansal S, et al. Association between antibodies against lung self-antigens and gastroesophageal reflux in lung transplant candidates. Semin Thorac Cardiovasc Surg. 2023;35:177-86.
25. Sweet MP, Herbella FA, Leard L, et al. The prevalence of distal and proximal gastroesophageal reflux in patients awaiting lung transplantation. Ann Surg. 2006;244:491-7.
26. Leung R, Lo WK, Sharma NS, Goldberg HJ, Chan WW. Esophageal function and reflux evaluations in lung transplantation: a nationwide survey of UNOS-Accredited Transplant Centers in the United States. Clin Transl Gastroenterol. 2023;14:e00641.
27. Cantu E 3rd, Appel JZ 3rd, Hartwig MG, et al. J. Maxwell chamberlain memorial paper. early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease. Ann Thorac Surg. 2004;78:1142-51; discussion 1142.
28. Davidson JR, Franklin D, Kumar S, et al. Fundoplication to preserve allograft function after lung transplant: Systematic review and meta-analysis. J Thorac Cardiovasc Surg. 2020;160:858-66.
29. Robertson AG, Krishnan A, Ward C, et al. Anti-reflux surgery in lung transplant recipients: outcomes and effects on quality of life. Eur Respir J. 2012;39:691-7.
30. Biswas Roy S, Elnahas S, Serrone R, et al. Early fundoplication is associated with slower decline in lung function after lung transplantation in patients with gastroesophageal reflux disease. J Thorac Cardiovasc Surg. 2018;155:2762-2771.e1.
31. Snell GI, Yusen RD, Weill D, et al. Report of the ISHLT working group on primary lung graft dysfunction, part I: definition and grading-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2017;36:1097-103.
32. Hirji SA, Gulack BC, Englum BR, et al. Lung transplantation delays gastric motility in patients without prior gastrointestinal surgery - a single-center experience of 412 consecutive patients. Clin Transplant. 2017:31.
33. Masuda T, Mittal SK, Csucska M, et al. Esophageal aperistalsis and lung transplant: Recovery of peristalsis after transplant is associated with improved long-term outcomes. J Thorac Cardiovasc Surg. 2020;160:1613-26.
34. Howland AM. Gastroesophageal reflux disease management and chronic use of proton pump inhibitors. JAAPA. 2023;36:1-6.
35. Katz PO, Dunbar KB, Schnoll-Sussman FH, Greer KB, Yadlapati R, Spechler SJ. ACG Clinical Guideline for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2022;117:27-56.
36. Shin JM, Sachs G. Pharmacology of proton pump inhibitors. Curr Gastroenterol Rep. 2008;10:528-34.
37. Yadlapati R, Gyawali CP, Pandolfino JE; CGIT GERD Consensus Conference Participants. AGA Clinical practice update on the personalized approach to the evaluation and management of GERD: expert review. Clin Gastroenterol Hepatol. 2022;20:984-994.e1.
38. Zhang H, Yang Z, Ni Z, Shi Y. A meta-analysis and systematic review of the efficacy of twice daily PPIs versus once daily for treatment of gastroesophageal reflux disease. Gastroenterol Res Pract. 2017;2017:9865963.
39. Rackoff A, Agrawal A, Hila A, Mainie I, Tutuian R, Castell DO. Histamine-2 receptor antagonists at night improve gastroesophageal reflux disease symptoms for patients on proton pump inhibitor therapy. Dis Esophagus. 2005;18:370-3.
40. Ghebre YT, Raghu G. Idiopathic pulmonary fibrosis: novel concepts of proton pump inhibitors as antifibrotic drugs. Am J Respir Crit Care Med. 2016;193:1345-52.
41. Yoshida N, Yoshikawa T, Tanaka Y, et al. A new mechanism for anti-inflammatory actions of proton pump inhibitors--inhibitory effects on neutrophil-endothelial cell interactions. Aliment Pharmacol Ther. 2000;14 Suppl 1:74-81.
42. Khor YH, Bissell B, Ghazipura M, et al. Antacid medication and antireflux surgery in patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Ann Am Thorac Soc. 2022;19:833-44.
43. Raghu G, Yang ST, Spada C, Hayes J, Pellegrini CA. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest. 2006;129:794-800.
44. Costabel U, Behr J, Crestani B, et al. Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials. Respir Res. 2018;19:167.
45. Kreuter M, Spagnolo P, Wuyts W, et al. Antacid therapy and disease progression in patients with idiopathic pulmonary fibrosis who received pirfenidone. Respiration. 2017;93:415-23.
46. Kreuter M, Wuyts W, Renzoni E, et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med. 2016;4:381-9.
47. Sigterman KE, van Pinxteren B, Bonis PA, Lau J, Numans ME. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev. 2013;2013:CD002095.
48. Kinoshita Y, Ishimura N, Ishihara S. Advantages and disadvantages of long-term proton pump inhibitor use. J Neurogastroenterol Motil. 2018;24:182-96.
49. Fackler WK, Ours TM, Vaezi MF, Richter JE. Long-term effect of H2RA therapy on nocturnal gastric acid breakthrough. Gastroenterology. 2002;122:625-32.
50. Yadlapati R, DeLay K. Proton pump inhibitor-refractory gastroesophageal reflux disease. Med Clin North Am. 2019;103:15-27.
51. Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther. 2000;14:669-90.
52. Ren LH, Chen WX, Qian LJ, Li S, Gu M, Shi RH. Addition of prokinetics to PPI therapy in gastroesophageal reflux disease: a meta-analysis. World J Gastroenterol. 2014;20:2412-9.
53. Leiman DA, Riff BP, Morgan S, et al. Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis. Dis Esophagus. 2017;30:1-9.
54. Xi L, Zhu J, Zhang H, Muktiali M, Li Y, Wu A. The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: a meta-analysis. Esophagus. 2021;18:144-51.
55. Biswas M, Singh KNM, Shetty YC, Koli PG, Ingawale S, Bhatia SJ. Prescription pattern & adverse drug reactions of prokinetics. Indian J Med Res. 2019;149:748-54.
56. Costabel U, Bendstrup E, Cottin V, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther. 2014;31:375-91.
57. Pan L, Gelzleichter T, Chen Y, Burg C, Limb SL, Nguyen L. Effect of pirfenidone on gastric emptying in a rat model. Pulm Pharmacol Ther. 2018;51:41-7.
58. Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205:e18-47.
59. Frazzoni M, Piccoli M, Conigliaro R, Frazzoni L, Melotti G. Laparoscopic fundoplication for gastroesophageal reflux disease. World J Gastroenterol. 2014;20:14272-9.
60. Salvador R, Vittori A, Capovilla G, et al. Antireflux Surgery’s Lifespan: 20 years after laparoscopic fundoplication. J Gastrointest Surg. 2023;27:2325-35.
61. Linden PA, Gilbert RJ, Yeap BY, et al. Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg. 2006;131:438-46.
62. Raghu G, Morrow E, Collins BF, et al. Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre. Eur Respir J. 2016;48:826-32.
63. Callahan ZM, Amundson J, Su B, Kuchta K, Ujiki M. Outcomes after anti-reflux procedures: Nissen, Toupet, magnetic sphincter augmentation or anti-reflux mucosectomy?. Surg Endosc. 2023;37:3944-51.
64. Canto MI, Diehl DL, Parker B, et al. Outcomes of transoral incisionless fundoplication (TIF 2.0): a prospective multicenter cohort study in academic and community gastroenterology and surgery practices (with video). Gastrointest Endosc. 2025;101:90-102.e1.
65. Fass R, Cahn F, Scotti DJ, Gregory DA. Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of gastroesophageal reflux disease. Surg Endosc. 2017;31:4865-82.
66. Rodríguez L, Rodriguez P, Gómez B, et al. Two-year results of intermittent electrical stimulation of the lower esophageal sphincter treatment of gastroesophageal reflux disease. Surgery. 2015;157:556-67.
67. Halpern SE, Gupta A, Jawitz OK, et al. Safety and efficacy of an implantable device for management of gastroesophageal reflux in lung transplant recipients. J Thorac Dis. 2021;13:2116-27.
68. Kolbeinsson HM, Lawson C, Banks-Venegoni A, Girgis R, Scheeres DE. Treatment of gastroesophageal reflux disease after lung transplant using radiofrequency ablation to the lower esophageal sphincter (stretta procedure). Am Surg. 2022;88:1663-8.
69. Latorre-Rodríguez AR, Aschenbrenner E, Mittal SK. Magnetic sphincter augmentation may limit access to magnetic resonance imaging. Dis Esophagus. 2023;36:doad032.
70. Ardila-Gatas J, Sharma G, Nor Hanipah Z, et al. Bariatric surgery in patients with interstitial lung disease. Surg Endosc. 2019;33:1952-8.
71. Yuce TK, Ellis RJ, Merkow RP, Soper NJ, Bilimoria KY, Odell DD. Post-operative complications and readmissions following outpatient elective Nissen fundoplication. Surg Endosc. 2020;34:2143-8.
